Unichem Laboratories Ltd , a prominent player in the Indian pharmaceutical sector, has released its financial results for the half year ended September 30, showcasing revenue growth but a shift to net loss.

Financial Highlights

Unichem Laboratories demonstrated robust top-line growth in the first half, with consolidated revenue from operations increasing to ₹1,105.56 crores from ₹990.70 crores in the same period last year, marking an 11.6% year-over-year growth. This growth indicates strong market demand for the company's pharmaceutical products.

However, despite the positive trend in revenue, Unichem Laboratories reported a consolidated net loss of ₹22.36 crores for the half year. This stands in contrast to the net profit of ₹26.70 crores recorded in the same period of the previous year. The shift from profit to loss was primarily attributed to exceptional expenses of ₹58.26 crores related to interest on a European Commission fine.

European Commission Fine

The company and its subsidiary Niche Generics received a demand order from the European Commission for payment of fine and interest totaling Euro 19.55 million. This amount was fully settled on October 28, impacting the company's financial performance for the period.

Standalone Performance

On a standalone basis, Unichem Laboratories reported a net loss of ₹41.78 crores for the half year, further highlighting the challenges faced by the company during this period.

Corporate Restructuring

During the period, Unichem Ireland ceased to be a subsidiary effective April 30, resulting in a net gain of ₹1.99 crores for the company.

Corporate Governance and Transparency

As per the latest corporate filing, Unichem Laboratories' Board of Directors approved these unaudited financial statements at their meeting held on November 11. This prompt disclosure aligns with regulatory requirements and demonstrates the company's commitment to transparency and timely communication with its stakeholders.

The pharmaceutical sector continues to be a critical component of the Indian economy, and Unichem Laboratories' performance offers insights into the industry's dynamics. While the revenue growth is encouraging, the transition to a net loss position warrants attention from investors and analysts alike.

As the company navigates through these mixed results, stakeholders will likely look forward to management's insights on the factors contributing to the net loss, beyond the European Commission fine, and strategies for returning to profitability in the coming quarters.

Unichem Laboratories Limited, a prominent pharmaceutical company, has announced the completion of a significant financial settlement with the European Commission. The company has paid a fine of €16,753,873.41, including interest, related to the Perindopril drug matter.

Settlement Details

Background and Compliance

The payment follows a series of communications from Unichem Laboratories to its stakeholders. The company had previously informed about this matter through letters dated June 27, 2024, and September 18, 2025. This recent payment marks the conclusion of the issue that has been ongoing for over a year.

Regulatory Compliance

In adherence to regulatory requirements, Unichem Laboratories has duly notified the stock exchanges about the completion of this payment. This notification aligns with the company's obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Statement

Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories, confirmed the payment in an official communication to the stock exchanges. The statement reads, "Today, the company has made payment of fine (including interest) of Euro 16,753,873.41 to European Commission, Brussels, Belgium in the Perindopril drug matter."

This development represents a significant financial event for Unichem Laboratories and marks the resolution of a major regulatory issue with European authorities. The impact of this substantial fine on the company's financials and its implications for future operations in the European market remain to be seen.

Investors and stakeholders of Unichem Laboratories will likely be monitoring how this settlement affects the company's financial position and its strategies moving forward, particularly in the European pharmaceutical market.